Navigation Links
Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
Date:6/30/2011

CAMBRIDGE, Mass., June 30, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that it will present preclinical data on MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, and MM-398, a nanoliposomal encapsulation of irinotecan, at the 14th World Conference on Lung Cancer, taking place July 3 – 7, 2011, in Amsterdam, The Netherlands.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

MM-151MM-151 is designed to effectively block downstream signaling of the EGFR receptor, a key oncogene in various carcinomas. The poster will present pre-clinical data regarding the potency of MM-151 compared to existing monoclonal therapies targeting EGFR.Poster #3656 presents preclinical data on the ability of  MM-151 to effectively block EGFR pathway activation in in-vitro signaling and inhibit tumor cell growth in-vitro and in-vivo in lung cancer modelsPoster Session:  P2.070: Poster Session 2

Number:  3656

Date/Time:  Tuesday, July 5, from 12:15 PM – 2:00 PM

Location:  RAI Exhibition and Convention Centre, Exhibition HallMM-398  

MM-398 is designed to stably retain and protect irinotecan while in circulation in the body and enable efficient accumulation of the drug in solid tumors.  MM-398, in partnership with PharmaEngine, Inc., is in clinical development in colorectal, gastric and pancreatic cancer and in glioma.  The poster will present preclinical data on the safety and activity of MM-398 in lung cancer xenograft models.Poster #S420-421 presents preclinical data on MM-398's safety and activity Oral Session:  033.03: Preclinical Models 1

Number:  S420-421

Date/Time:  Wednesday, July 6, from 2:30 PM – 4:00 PM

Location:  Room D201Ab
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
2. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
3. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
4. Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
6. Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
7. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
8. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
9. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
11. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... The fully automated supercritical fluidic ... sequentially analyze up to 48 samples utilizing automatic ... of targets by mass spectrometry. , The ... measurement requirements of a wide range of applications, ... and search for disease biomarkers, additives in forming ...
(Date:2/27/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... with patients and health care advocates in the United ... Day®. Rare Disease Day is dedicated to elevating ... the special challenges faced by patients with rare diseases ... proud to stand alongside patients and caregivers representing the ...
(Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
(Date:2/26/2015)... 26, 2015   Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... and Chief Executive Officer of Regulus, will present a ... Annual Healthcare Conference on Wednesday, March 4, 2015 ... at the Boston Marriott Copley Place.  ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... Funds to Be Used for Phase 1 Clinical Trial ... a privately-held,radiopharmaceuticals company that designs and develops products to ... has raised $13,million in a private offering. Cellectar will ... 1 clinical trial for its lead oncology,product candidate, CLR1404, ...
... WiMAX Broadband Wireless Technology, Will, Provide Free Internet Access to ... ... College, PETACH TIKVA, Israel, January 8 012,Smile.Communications (NASDAQ: ... today announced that it has joined,with Israel,s Ministry of Communications, ...
... and tiny iron-bearing particles to drive healthy cells to ... animals, may lead to a new method of delivering ... in people. , The study team, led by Robert ... Pediatric Cardiology at The Childrens Hospital of Philadelphia, loaded ...
Cached Biology Technology:Cellectar, Inc. Raises $13 Million in Private Offering 2Cellectar, Inc. Raises $13 Million in Private Offering 3Israel's Ministry of Communications, 012 Smile.Communications, Intel and Alvarion Join in Launching WiMAX Initiative for Sderot, a City in the Western Negev 2Israel's Ministry of Communications, 012 Smile.Communications, Intel and Alvarion Join in Launching WiMAX Initiative for Sderot, a City in the Western Negev 3Israel's Ministry of Communications, 012 Smile.Communications, Intel and Alvarion Join in Launching WiMAX Initiative for Sderot, a City in the Western Negev 4Israel's Ministry of Communications, 012 Smile.Communications, Intel and Alvarion Join in Launching WiMAX Initiative for Sderot, a City in the Western Negev 5Researchers use magnetism to target cells to animal arteries 2Researchers use magnetism to target cells to animal arteries 3
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)... Wis. , Jan. 15, 2015  BellBrook Labs, ... drug discovery, announced the launch of a TR-FRET ... the company,s Transcreener UDP Assay, a high throughput ... The new assay will allow for sensitive detection ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... EVANSTON, Ill. --- A Northwestern University research team ... could be used to deliver chemotherapy drugs locally ... removed. The flexible microfilm device, which ... be customized easily into different shapes, has the ...
... planning of the preparatory activities for a new tentative ... satellite. On 7 September, preparatory activities for the ... Russia were stopped by Eurockot due to an anomaly ... and navigation subsystem of the launcher,s Upper Stage Breeze ...
... reveal an electromagnetic marker that predicts a patient,s ... "Such biomarkers that identify who will benefit ... minimize trial-and-error prescribing and speed delivery of care ... Carlos Zarate, M.D., of the National Institute of ...
Cached Biology News:Nanodiamond drug device could transform cancer treatment 2Nanodiamond drug device could transform cancer treatment 3Millisecond brain signals predict response to fast-acting antidepressant 2
...
... Edited by R. Edwards ... on all types of immunoassays, ... surface immunoassays and on the ... immunoassays. Essential information is also ...
ANTI S. ENTERID LPS...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Biology Products: